Schizotypal Personality Disorder Clinical Trial
Official title:
The Dopaminergic System in Schizotypal Personality Disorder: Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
Hypothesis: Schizotypal personality disorder patients will show cognitive improvements in 1)
working memory 2) learning and memory 3) sustained attention 4) enhanced performance on the
AX-CPT, N-back and Eriksen during pergolide treatment. There will be a significant diagnosis
by drug administration of 0.3 mg of oral pergolide interaction for performance on the
cognitive tasks, with the schizotypal personality disorder group demonstrating significantly
improved peformance compared to the other personality disorder group after pergolide
compared with placebo.
Design: Randomized, double-blind, crossover study of pergolide vs. placebo. Half of subjects
receive pergolide for eight weeks; half of subjects receive placebo for four weeks followed
by pergolide for four weeks.
n/a
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02149823 -
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
|
Phase 1 | |
| Terminated |
NCT00353379 -
Pharmacology of Cognition in Schizotypal Personality Disorder
|
Phase 4 | |
| Recruiting |
NCT05710926 -
Evolutionary Systems Therapy for Schizotypy
|
N/A | |
| Completed |
NCT00158028 -
Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder
|
N/A | |
| Completed |
NCT02800681 -
Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult Sample
|
||
| Completed |
NCT02524899 -
CRT-Guanfacine for SPD
|
Phase 2 | |
| Recruiting |
NCT01466205 -
Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder
|
Phase 2 | |
| Completed |
NCT02535156 -
Schizotypal Personality Disorder Risperidone
|
Phase 1/Phase 2 | |
| Completed |
NCT04764708 -
Compassion and Metacognition in Schizotypal Personality
|
N/A | |
| Completed |
NCT02507206 -
A D1 Agonist For Working Memory
|
Phase 2 |